Fusion of HSV-1 VP22 to a bifunctional chimeric SuperCD suicide gene compensates for low suicide gene transduction efficiencies

International Journal of Oncology

Volumn 30, Issue 5, 2007, Pages 1153-1161

  Lemken, Marie Luise ^a   Graepler, Florian ^a   Wolf, Claudia ^a   Wybranietz, Wolfgang A ^a   Smirnow, Irina ^a   Schmidt, Ulrike ^a   Gregor, Michael ^a   Bitzer, Michael ^a   Lauer, Ulrich M ^a  

^a UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

Author keywords

Bystander effect; HSV 1; Suicide gene; VP22

Indexed keywords

CYTOSINE DEAMINASE; FLUCYTOSINE; HERPES SIMPLEX VIRUS TYPE 1 PROTEIN VP22; HYBRID PROTEIN; UNCLASSIFIED DRUG; VIRUS PROTEIN;

ADENOVIRUS; ANIMAL; ARTICLE; CELL LINE; CELL STRAIN COS1; CERCOPITHECUS; CHEMISTRY; COCULTURE; DOSE RESPONSE; GENETIC PROCEDURES; HELA CELL; HUMAN; IC 50; RAT; TUMOR CELL LINE;

ADENOVIRIDAE; ANIMALS; CELL LINE; CELL LINE, TUMOR; CERCOPITHECUS AETHIOPS; COCULTURE TECHNIQUES; COS CELLS; CYTOSINE DEAMINASE; DOSE-RESPONSE RELATIONSHIP, DRUG; FLUCYTOSINE; GENETIC TECHNIQUES; HELA CELLS; HUMANS; INHIBITORY CONCENTRATION 50; RATS; RECOMBINANT FUSION PROTEINS; VIRAL STRUCTURAL PROTEINS;

EID: 34447296503     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.30.5.1153     Document Type: Article

References (43)

1. Dachs GU, Tupper J and Tozer GM: From bench to bedside for gene-directed enzyme prodrug therapy of cancer. Anticancer Drugs 16: 349-359, 2005. (Pubitemid 40434601)
2. Mullen CA, Kilstrup M and Blaese RM: Transfer of the bacterial gene for cytosine deaminase to mammalian cells confers lethal sensitivity to 5-fluorocytosine: a negative selection system. Proc Natl Acad Sci USA 89: 33-37, 1992.
3. Wadhwa PD, Zielske SP, Roth JC, Ballas CB, Bowman JE and Gerson SL: Cancer gene therapy: scientific basis. Annu Rev Med 53: 437-452, 2002. (Pubitemid 34177890)
4. Seth P: Vector-mediated cancer gene therapy: an overview. Cancer Biol Ther 4: 512-517, 2005. (Pubitemid 41351222)
5. Huber BE, Austin EA, Richards CA, Davis ST and Good SS: Metabolism of 5-fluorocytosine to 5-fluorouracil in human colorectal tumor cells transduced with the cytosine deaminase gene: significant antitumor effects when only a small percentage of tumor cells express cytosine deaminase. Proc Natl Acad Sci USA 91: 8302-8306, 1994.
6. Lumniczky K and Safrany G: Cancer gene therapy: combination with radiation therapy and the role of bystander cell killing in the anti-tumor effect. Pathol Oncol Res 12: 118-124, 2006. (Pubitemid 44197182)
7. Elliott GD and Meredith DM: The herpes simplex virus type 1 tegument protein VP22 is encoded by gene UL49. J Gen Virol 73: 723-726, 1992.
8. Elliott G and O'Hare P: Intercellular trafficking and protein delivery by a Herpesvirus structural protein. Cell 88: 223-233, 1997. (Pubitemid 28015871)
9. Dilber MS, Phelan A, Aints A, Mohamed AJ, Elliott G, Smith CI and O'Hare P: Intercellular delivery of thymidine kinase prodrug activating enzyme by the herpes simplex virus protein, VP22. Gene Ther 6: 12-21, 1999.
10. Kong BH, Wang WX, Liu CS, Song L, Ma DX, Qu X, Jiang J, Yang XS, Zhang YZ, Wang B, Wei MQ and Yang QF: Efficacy of Lentivirus-mediated and MUC1 antibody-targeted VP22-TK/GCV suicide gene therapy for ovarian cancer. In Vivo 17: 153-156, 2003.
11. Wybranietz WA, Gross CD, Phelan A, O'Hare P, Spiegel M, Graepler F, Bitzer M, Stahler P, Gregor M and Lauer UM: Enhanced suicide gene effect by adenoviral transduction of a VP22-cytosine deaminase (CD) fusion gene. Gene Ther 8: 1654-1664, 2001.
12. Lee KC, Hamstra DA, Bullarayasamudram S, Bhojani MS, Moffat BA, Dornfeld KJ, Ross BD and Rehemtulla A: Fusion of the HSV-1 tegument protein vp22 to cytosine deaminase confers enhanced bystander effect and increased therapeutic benefit. Gene Ther 13: 127-137, 2006.
13. Kievit E, Bershad E, Ng E, Sethna P, Dev I, Lawrence TS and Rehemtulla A: Superiority of yeast over bacterial cytosine deaminase for enzyme/prodrug gene therapy in colon cancer xenografts. Cancer Res 59: 1417-1421, 1999.
14. Erbs P, Regulier E, Kintz J, Leroy P, Poitevin Y, Exinger F, Jund R and Mehtali M: In vivo cancer gene therapy by adenovirus-mediated transfer of a bifunctional yeast cytosine deaminase/uracil phosphoribosyltransferase fusion gene. Cancer Res 60: 3813-3822, 2000.
15. Graepler F, Lemken ML, Wybranietz WA, Schmidt U, Smirnow I, Gross CD, Spiegel M, Schenk A, Graf H, Lauer UA, Vontheim R, Gregor M, Armeanu S, Bitzer M and Lauer UM: Bifunctional chimeric SuperCD suicide gene - YCD: YUPRT fusion is highly effective in a rat hepatoma model. World J Gastroenterol 11: 6910-6919, 2005.
16. Chartier C, Degryse E, Gantzer M, Dieterle A, Pavirani A and Mehtali M: Efficient generation of recombinant adenovirus vectors by homologous recombination in Escherichia coli. J Virol 70: 4805-4810, 1996. (Pubitemid 26187479)
17. He TC, Zhou S, Da Costa LT, Yu J, Kinzler KW and Vogelstein B: A simplified system for generating recombinant adenoviruses. Proc Natl Acad Sci USA 95: 2509-2514, 1998. (Pubitemid 28145972)
18. Lusky M, Christ M, Rittner K, Dieterle A, Dreyer D, Mourot B, Schultz H, Stoeckel F, Pavirani A and Mehtali M: In vitro and in vivo biology of recombinant adenovirus vectors with E1, E1/E2A, or E1/E4 deleted. J Virol 72: 2022-2032, 1998.
19. Graham FL and Prevec L: Methods for construction of adenovirus vectors. Mol Biotechnol 3: 207-220, 1995.
20. Zhang WW, Koch PE and Roth JA: Detection of wild-type contamination in a recombinant adenoviral preparation by PCR. Biotechniques 18: 444-447, 1995.
21. Skehan P, Storeng R, Monks A, McMahon J, Vistica D, Warren JT, Bokesch H, Kenney S and Boyd MR: New colorimetric cytotoxicity assay for anticancer-drug screening. J Natl Cancer Inst 82: 1107-1112, 1990. (Pubitemid 20213250)
22. Kaplan JM: Adenovirus-based cancer gene therapy. Curr Gene Ther 5: 595-605, 2005.
23. Adachi Y, Tamiya T, Ichikawa T, Terada K, Ono Y, Matsumoto K, Furuta T, Hamada H and Ohmoto T: Experimental gene therapy for brain tumors using adenovirus-mediated transfer of cytosine deaminase gene and uracil phosphoribosyltransferase gene with 5-fluorocytosine. Hum Gene Ther 11: 77-89, 2000. (Pubitemid 30044042)
24. Elliott G and O'Hare P: Intercellular trafficking of VP22-GFP fusion proteins. Gene Ther 6: 149-151, 1999. (Pubitemid 29043706)
25. Greco O, Joiner MC, Doleh A and Scott SD: VP22-mediated intercellular transport for suicide gene therapy under oxic and hypoxic conditions. Gene Ther 12: 974-979, 2005.
26. Liu CS, Kong B, Xia HH, Ellem KA and Wei MQ: VP22 enhanced intercellular trafficking of HSV thymidine kinase reduced the level of ganciclovir needed to cause suicide cell death. J Gene Med 3: 145-152, 2001.
27. Qiu Z, Zhu J, Harms JS, Friedrichsen J and Splitter GA: Bovine Herpesvirus VP22 induces apoptosis in neuroblastoma cells by upregulating the expression ratio of Bax to Bcl-2. Hum Gene Ther 16: 101-108, 2005.
28. Qiu Z, Harms JS, Zhu J and Splitter GA: Bovine herpesvirus tegument protein VP22 enhances thymidine kinase/ganciclovir suicide gene therapy for neuroblastomas compared to herpes simplex virus VP22. J Virol 78: 4224-4233, 2004.
29. Hakkarainen T, Wahlfors T, Merilainen O, Loimas S, Hemminki A and Wahlfors J: VP22 does not significantly enhance enzyme prodrug cancer gene therapy as a part of a VP22-HSVTk-GFP triple fusion construct. J Gene Med 7: 898-907, 2005.
30. Zender L, Kühnel F, Kock R, Manns M and Kubicka S: VP22-mediated intercellular transport of p53 in hepatoma cells in vitro and in vivo. Cancer Gene Ther 9: 489-496, 2002.
31. Zavaglia D, Favrot MC, Eymin B, Tenaud C and Coll JL: Intercellular trafficking and enhanced in vivo antitumour activity of a non-virally delivered P27-VP22 fusion protein. Gene Ther 10: 314-325, 2003.
32. Phelan A, Elliott G and O'Hare P: Intercellular delivery of functional p53 by the herpesvirus protein VP22. Nat Biotechnol 16: 440-443, 1998.
33. Green KL, Southgate TD, Mulryan K, Fairbairn LJ, Stern PL and Gaston K: Diffusible VP22-E2 protein kills bystander cells and offers a route for cervical cancer gene therapy. Hum Gene Ther 17: 147-157, 2006.
34. Lundberg M and Johansson M: Is VP22 nuclear homing an artifact? Nat Biotechnol 19: 713-714, 2001.
35. Fang B, Xu B, Koch P and Roth JA: Intercellular trafficking of VP22-GFP fusion proteins is not observed in cultured mammalian cells. Gene Ther 5: 1420-1424, 1998.
36. Roy V, Qiao J, Campos-Lima P and Caruso M: Direct evidence for the absence of intercellular trafficking of VP22 fused to GFP or to the herpes simplex virus thymidine kinase. Gene Ther 12: 169-176, 2004.
37. Zavaglia D, Lin EH, Guidetti M, Pluquet O, Hainaut P, Favrot MC and Coll JL: Poor intercellular transport and absence of enhanced antiproliferative activity after non-viral gene transfer of VP22-P53 or P53-VP22 fusions into p53 null cell lines in vitro or in vivo. J Gene Med 7: 936-944, 2005.
38. Lemken ML, Wolf C, Wybranietz WA, Schmidt U, Smirnow I, Bühring HJ, Mack AF, Lauer UM and Bitzer M: Evidence for the presence of intercellular trafficking of VP22 in living cells. Mol Ther 15: 310-319, 2007.
39. Wybranietz WA, Prinz F, Spiegel M, Schenk A, Bitzer M, Gregor M and Lauer UM: Quantification of VP22-GFP spread by direct fluorescence in 15 commonly used cell lines. J Gene Med 1: 265-274, 1999.
40. Brewis N, Phelan A, Webb J, Drew J, Elliott G and O'Hare P: Evaluation of VP22 spread in tissue culture. J Virol 74: 1051-1056, 2000.
41. Aints A, Dilber MS and Smith CI: Intercellular spread of GFP-VP22. J Gene Med 1: 275-279, 1999.
42. Bitzer M and Lauer UM: Oncolytic viruses for genetic therapy of gastrointestinal tumors. Z Gastroenterol 41: 667-674, 2003.
43. Everts B and van der Poel HG: Replication-selective oncolytic viruses in the treatment of cancer. Cancer Gene Ther 12: 141-161, 2005.